ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,350Medicare Part D Prescriptions Filled, Including Refills

Rank: 31 out of 229

$543K Total Retail Price of All Prescriptions

Rank: 38 out of 229

892 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
16% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 892 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

9% of this provider’s 892 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

4% of this provider’s 9,075 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$52 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LEVOTHYROXINE SODIUM 881 794 1 1
SIMVASTATIN 514 460 2 3
LISINOPRIL 414 371 3 2
PRAVASTATIN SODIUM 383 336 4 25
AMLODIPINE BESYLATE 316 292 5 5
CITALOPRAM HBR 286 262 6 21
METFORMIN HCL 279 243 7 6
OMEPRAZOLE 259 215 8 4
HYDROCODONE-ACETAMINOPHEN 250 202 S3 9 7
HYDROCHLOROTHIAZIDE 220 204 10 9
GABAPENTIN 178 145 11 10
FLUTICASONE PROPIONATE 170 156 12 23
LOVASTATIN 162 160 13 11
LOSARTAN POTASSIUM 158 150 14 12
ATENOLOL 150 138 15 19
METOPROLOL TARTRATE 134 134 16 13
ALENDRONATE SODIUM 133 126 17 14
TRAMADOL HCL 127 100 18 26
TRAZODONE HCL 123 90 19 34
METOPROLOL SUCCINATE 112 102 20 16
CRESTOR 109 91 21 30
WARFARIN SODIUM 108 96 22 17
TRIAMTERENE-HCTZ 107 102 23 51
PAROXETINE HCL 100 93 24 49
PANTOPRAZOLE SODIUM 91 83 25 33
FENOFIBRATE 90 78 26 68
FLUOXETINE HCL 81 73 27 41
DOXAZOSIN MESYLATE 80 80 28 50
CYCLOBENZAPRINE HCL 78 73 R 29 75
RANITIDINE HCL 78 76 29 32
LISINOPRIL-HYDROCHLOROTHIAZIDE 78 75 29 28
GEMFIBROZIL 78 50 29 62
DONEPEZIL HCL 77 75 33 29
AMITRIPTYLINE HCL 73 72 R 34 66
ALLOPURINOL 69 64 35 27
FUROSEMIDE 65 57 36 8
HYDRALAZINE HCL 64 58 37 78
MELOXICAM 61 45 38 45
PROAIR HFA 60 28 39 38
ZOLPIDEM TARTRATE 60 51 39 20
ATORVASTATIN CALCIUM 57 57 41 15
PROPRANOLOL HCL 56 37 42 127
SYNTHROID 54 54 43 46
PREMARIN 51 50 R 44 101
SERTRALINE HCL 51 48 44 22
BENICAR 51 48 44 148
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 15, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.